AURKA and neuroblastoma: Nonetheless,the optimized compounds SK4454 and SK5527 presented here provide a strong foundation for continued preclinicalstudies aimed at validating AURKA degradation as a therapeutic strategyin neuroblastoma and other AURKA-driven malignancies.